The "1st septal unit" in hypertrophic obstructive cardiomyopathy: A newly recognized anatomo-functional entity, identified during recent alcohol septal ablation experience

Texas Heart Institute Journal

Volumn 34, Issue 3, 2007, Pages 336-346

  Angelini, Paolo ^a,b,c  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Alcohol septal ablation; Asymmetric septal hypertrophy; Cardiomyopathy, hypertrophic obstructive physiopathology therapy; Coronary vessels anatomy; Ethanol therapeutic use; First septal unit; Heart septum

Indexed keywords

ALCOHOL;

ANGIOCARDIOGRAPHY; AORTA STENOSIS; BALLOON CATHETER; CATHETER ABLATION; CLINICAL FEATURE; CORONARY ARTERY BLOOD FLOW; HEART ARRHYTHMIA; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MYOMECTOMY; PATHOPHYSIOLOGY; REVIEW;

CARDIOMYOPATHY, HYPERTROPHIC; COMORBIDITY; CORONARY ANGIOGRAPHY; CORONARY VESSEL ANOMALIES; DISCRETE SUBAORTIC STENOSIS; ETHANOL; HEART SEPTUM; HUMANS; MAGNETIC RESONANCE IMAGING;

EID: 35848932974     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211-4.
2. Shamim W, Yousufuddin M, Wang D, Henein M, Seggewiss H, Flather M, et al. Nonsurgical reduction of the interventricular septum in patients with hypertrophic cardiomyopathy. N Engl J Med 2002;347:1326-33.
3. [Retraction in: Coats AJ, Henein M, Flather M, Sigwart U, Seggewiss H, Wang D, et al. N Engl J Med 2003;348:951.]
4. Knight C, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Harrington D, et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 1997;95:2075-81.
5. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 1998;31:252-8.
6. Seggewiss H, Faber L, Gleichmann U. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. Thorac Cardiovasc Surg 1999;47:94-100.
7. Ruzyllo W, Chojnowska L, Demkow M, Witkowski A, Kusmierczyk-Droszcz B, Piotrowski W, et al. Left ventricular out flow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy. Eur Heart J 2000;21:770-7.
8. Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH 3rd. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. J Am Coll Cardiol 2000;36:852-5.
9. Airoldi F, Di Mario C, Catanoso A, Dharmadhikari A, Tzifos V, Anzuini A, et al. Progressive decrease of outflow gradient and septum thickness after percutaneous alcoholization of the interventricular septum in hypertrophic obstructive cardiomyopathy. Ital Heart J 2000;1:200-6.
10. Mazur W, Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Roberts R, Spencer WH 3rd. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 2001;103:1492-6.
11. Bhagwandeen R, Woo A, Ross J, Wigle ED, Rakowski H, Kwinter J, et al. Septal ethanol ablation for hypertrophic obstructive cardiomyopathy: early and intermediate results of a Canadian referral centre. Can J Cardiol 2003;19:912-7.
12. Chang SM, Lakkis NM, Franklin J, Spencer WH 3rd, Nagueh SF. Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation 2004;109:824-7.
13. Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001;38:1701-6.
14. Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Zoghbi WA, Quinones MA, Spencer WH 3rd. Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 1999;99:344-7.
15. Seggewiss H, Rigopoulos A, Faber L, Ziemssen P. Alcohol septal ablation. In: Maron BJ, editor. Diagnosis and management of hypertrophic cardiomyopathy: sudden death prevention. Malden (MA): Blackwell Futura; 2004. p. 259-78.
16. Brugada P, de Swart H, Smeets JL, Wellens HJ. Transcoronary chemical ablation of ventricular tachycardia. Circulation 1989;79:475-82.
17. Autore C, Bernabo P, Barilla CS, Bruzzi P, Spirito P. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol 2005;45:1076-80.
18. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:1778-85.
19. Firoozi S, Elliott PM, Sharma S, Murday A, Brecker SJ, Hamid MS, et al. Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. Eur Heart J 2002;23:1617-24.
20. Beahrs MM, Tajik AJ, Seward JB, Giuliani ER, McGoon DC. Hypertrophic obstructive cardiomyopathy: ten- to 21-year follow-up after partial septal myectomy. Am J Cardiol 1983;51:1160-6.
21. Cohn LH, Trehan H, Collins JJ Jr. Long-term follow-up of patients undergoing myotomy/myectomy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 1992;70:657-60.
22. Mohr R, Schaff HV, Danielson GK, Puga FJ, Pluth JR, Tajik AJ. The outcome of surgical treatment of hypertrophic obstructive cardiomyopathy. Experience over 15 years. J Thorac Cardiovasc Surg 1989;97:666-74.
23. Schoendube FA, Klues HG, Reith S, Messmer BJ. Surgical correction of hypertrophic obstructive cardiomyopathy with combined myectomy, mobilisation and partial excision of the papillary muscles. Eur J Cardiothorac Surg 1994;8:603-8.
24. Heric B, Lytle BW, Miller DP, Rosenkranz ER, Lever HM, Cosgrove DM. Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results. J Thorac Cardiovasc Surg 1995;110:195-208.
25. Robbins RC, Stinson EB. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 1996;111:586-94.
26. Schulte HD, Borisov K, Gams E, Gramsch-Zabel H, Losse B, Schwartzkopff B. Management of symptomatic hypertrophic obstructive cardiomyopathy - long-term results after surgical therapy. Thorac Cardiovasc Surg 1999;47:213-8.
27. Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Gersh BJ, Nishimura RA. The case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;44:2044-53.
28. Woo A, Williams WG, Choi R, Wigle ED, Rozenblyum E, Fedwick K, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 2005;111:2033-41.
29. Elliott PM, Brecker SJ, McKenna WJ. Left ventricular opacification during selective intracoronary injection of echo cardiographic contrast in patients with hypertrophic cardiomyopathy. Heart 2000;83:E7.
30. Monakier D, Horlick E, Ross J, Woo A, Rakowski H, Schwartz L, et al. Intracoronary myocardial contrast echocardiography in a patient with drug refractory hypertrophic obstructive cardiomyopathy revealing extensive myocardium at risk for infarction with alcohol septal ablation. J Invasive Cardiol 2004;16:482-4.
31. Morrow AG, Braunwald E. Functional aortic stenosis; a malformation characterized by resistance to left ventricular outflow without anatomic obstruction. Circulation 1959;20:181-9.
32. Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H, Williams WG. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis 1985;28:1-83.
33. Murgo JP, Alter BR, Dorethy JF, Altobelli SA, McGranahan GM Jr. Dynamics of left ventricular ejection in obstructive and nonobstructive hypertrophic cardiomyopathy. J Clin Invest 1980;66:1369-82.
34. Ross J Jr, Braunwald E, Gault JH, Mason DT, Morrow AG. The mechanism of the intraventricular pressure gradient in idiopathic hypertrophic subaortic stenosis. Circulation 1966;34:558-78.
35. Henry WL, Clark CE, Epstein SE. Asymmetric septal hypertrophy (ASH): the unifying link in the IHSS disease spectrum. Observations regarding its pathogenesis, pathophysiology, and course. Circulation 1973;47:827-32.
36. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995;26:1699-708.
37. Maron BJ, Harding AM, Spirito P, Roberts WC, Waller BF. Systolic anterior motion of the posterior mitral leaflet: a previously unrecognized cause of dynamic subaortic obstruction in patients with hypertrophic cardiomyopathy. Circulation 1983;68:282-93.
38. Klues HG, Roberts WC, Maron BJ. Morphological determinants of echocardiographic patterns of mitral valve systolic anterior motion in obstructive hypertrophic cardiomyopathy. Circulation 1993;87:1570-9.
39. Roberts R, Sigwart U. New concepts in hypertrophic cardiomyopathies, part I. Circulation 2001;104:2113-6.
40. Levine RA. Echocardiographic assessment of the cardiomyopathies. In: Weyman AE, editor. Principles and practice of echocardiography. Philadelphia: Lea & Febiger; 1994. p. 798-803.
41. Burri H, Sigwart U. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy. In: Hermann HC, editor. Contemporary cardiology; percutaneous noncoronary interventions. Totowa (NJ): Humana Press; 2005. p. 259-69.
42. Fulton WFM. The coronary arteries; arteriography, microanatomy, and pathogenesis of obliterative coronary artery disease. Springfield (IL): Charles C. Thomas; 1965. p. 83-8.
43. Sahni D, Jit I. Blood supply of the human interventricular septum in north-west Indians [published erratum appears in Indian Heart J 1990;42:334]. Indian Heart J 1990;42:161-9.
44. Angelini P, Villason S, Chan AV Jr, Diez JG. Normal and anomalous coronary arteries in humans. In: Angelini P, editor. Coronary artery anomalies: a comprehensive approach. Baltimore: Lippincott Williams & Wilkins; 1999. p. 27-150.
45. Hosseinpour AR, Anderson RH, Ho SY. The anatomy of the septal perforating arteries in normal and congenitally malformed hearts. J Thorac Cardiovasc Surg 2001;121:1046-52.
46. Singh M, Edwards WD, Holmes DR Jr, Tajil AJ, Nishimura RA. Anatomy of the first septal perforating artery: a study with implications for ablation therapy for hypertrophic cardiomyopathy. Mayo Clin Proc 2001;76:799-802.
47. Kuhn H, Gietzen F, Leuner C, Gerenkamp T. Induction of subaortic septal ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Studies to develop a new catheter-based concept of treatment. Eur Heart J 1997;18:846-51.
48. Fifer MA, Yoerger DM, Picard MH, Vlahakes GJ, Palacios IF. Images in cardiovascular medicine. Covered stent septal ablation for hypertrophic obstructive cardiomyopathy: initial success but ultimate failure resulting from collateral formation. Circulation 2003;107:3248-9.
49. Iacob M, Pinte F, Tintoiu I, Cotuna L, Caroescu M, Popa A, et al. Microcoil embolisation for ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy. Kardiol Pol 2004;61:350-5.
50. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation 1998;98:2415-21.
51. Said M, Muhlberger VA. The descending septal branch (Bonapace's branch). A case report and literature review of this often forgotten branch. First description in vivo. Eur Heart J 1995;16:1443-7.
52. Qin JX, Shiota T, Lever HM, Asher CR, Popovic ZB, Greenberg NL, et al. Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal reduction interventions. Am J Cardiol 2004;93:171-5.
53. Chang SM, Nagueh SF, Spencer WH 3rd, Lakkis NM. Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol 2003;42:296-300.
54. Chen AA, Palacios IF, Mela T, Yoerger DM, Picard MH, Vlahakes G, et al. Acute predictors of subacute complete heart block after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 2006;97:264-9.
55. Schwarz ER, Klues HG, vom Dahl J, Klein I, Krebs W, Hanrath P. Functional, angiographic and intracoronary Doppler flow characteristics in symptomatic patients with myocardial bridging: effect of short-term intravenous beta-blocker medication. J Am Coll Cardiol 1996;27:1637-45.
56. Raute-Kreinsen U. Morphology of necrosis and repair after transcoronary ethanol ablation of septal hypertrophy. Pathol Res Pract 2003;199:121-7.
57. Batalis NI, Harley RA, Collins KA. Iatrogenic deaths following treatment for hypertrophic obstructive cardiomyopathy: case reports and an approach to the autopsy and death certification. Am J Forensic Med Pathol 2005;26:343-8.
58. Wykrzykowska JJ, Kwaku K, Wylie J, Manning WJ, Josephson ME, Zimetbaum P, Laham RJ. Delayed occurrence of unheralded phase IV complete heart block after ethanol septal ablation for symmetric hypertrophic obstructive cardiomyopathy. Pacing Clin Electrophysiol 2006;29:674-8.
59. Veselka J, Duchonova R, Prochazkova S, Homolova I, Palenickova J, Zemanek D, et al. The biphasic course of changes of left ventricular outflow gradient after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Kardiol Pol 2004;60:133-7.
60. Yoerger DM, Picard MH, Palacios IF, Vlahakes GJ, Lowry PA, Fifer MA. Time course of pressure gradient response after first alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 2006;97:1511-4.
61. Schulz-Menger J, Strohm O, Waigand J, Uhlich F, Dietz R, Friedrich MG. The value of magnetic resonance imaging of the left ventricular outflow tract in patients with hypertrophic obstructive cardiomyopathy after septal artery embolization. Circulation 2000;101:1764-6.
62. Franke A, Kuhl HP, Schoendube FA. MRI versus 3D echocardiography in postinterventional patients with hypertrophic obstructive cardiomyopathy. Circulation 2001;104:E32-3.
63. Amano Y, Takayama M, Amano M, Kumazaki T. MRI of cardiac morphology and function after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. AJR Am J Roentgenol 2004;182:523-7.
64. Sitges M, Qin JX, Lever HM, Bauer F, Drinko JK, Agler DA, et al. Evaluation of left ventricular outflow tract area after septal reduction in obstructive hypertrophic cardiomyopathy: a real-time 3-dimensional echocardiographic study. Am Heart J 2005;150:852-8.
65. Mazur W, Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Roberts R, Spencer WH 3rd. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 2001;103:1492-6.
66. Lamke GT, Allen RD, Edwards WD, Tazelaar HD, Danielson GK. Surgical pathology of subaortic septal myectomy associated with hypertrophic cardiomyopathy. A study of 204 cases (1996-2000). Cardiovasc Pathol 2003;12:149-58.
67. Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342:365-73.